Ketamine for Treatment-Resistant Depression: Neurobiology and Applications

by Gustavo H. Vazquez PhD, Carlos A. Zarate, Elisa Brietzke

Overview

Ketamine for Treatment-Resistant Depression: Neurobiology and Applications provides a simple, evidence-based overview for neuropsychiatrists and translational researchers on this medication, its mechanisms of actions, eligibility of patients for treatment, and the preparation and implementation of ketamine clinics.

Product Details

ISBN-13:	9780128210338
Publisher:	Elsevier Science
Publication date:	09/18/2020
Pages:	168
Sales rank:	689,389
Product dimensions:	7.50(w) x 9.25(h) x (d)

About the Author

Gustavo H. Vazquez is a Full Professor at the School of Medicine, Queen's University, Director of the CME and staff member of the Mood Disorders Research and Treatment Service, Department of Psychiatry, Providence Care Hospital, Kingston, ON, Canada. He is a member of the Centre for Neuroscience Studies (CNS) at Queen's University (Kingston, Canada), member of the Centre of Neurosicence at Palermo University (Buenos Aires, Argentina) and member of the International Consortium for Psychotic and Bipolar Disorders Research at McLean Hospital, Harvard Medical School (Boston, United States of America).

Dr. Zarate completed his residency training in psychiatry at the Massachusetts Mental Health Center/Brockton VAMC division. He later completed a fellowship in Clinical Psychopharmacology at McLean Hospital of the Consolidated Department of Psychiatry, Harvard Medical School and remained on staff at McLean Hospital as the Director of the Bipolar and Psychotic Disorders Outpatient Services. From 1998 to 2000 Dr. Zarate was the Chief of the Bipolar and Psychotic Disorders Program at the University of Massachusetts Medical School. In 2001, he joined the Mood and Anxiety Disorders Program at NIMH. His achievements and awards include the Ethel-DuPont Warren Award and Livingston Awards, Consolidated Department of Psychiatry, Harvard Medical School; Outstanding Psychiatrist Research Award, Massachusetts Psychiatric Association; Program for Minority Research Training in Psychiatry, APA; the National Alliance for Research on Schizophrenia and Depression Young Investigator Award; National Alliance for Research on Schizophrenia and Depression Independent Investigator Award; the National Institutes of Health Director’s Award Scientific/Medical, the 2011 Brain & Behavior Research Foundation Award for Bipolar Mood Disorder Research, the 2013 National Institute of Health Director’s Award—Scientific/Medical Achievement and Mogens Schou Research Award: Bipolar Disorder and the Simon-Bolivar Award American Psychiatric Association; 2015 Ruth L. Kirschtein Mentoring Award NIH and the Astute Clinician Lecture Award, NIH; the 2019 ACNP Dolores Shockley Minority Mentoring Award; and in 2019 was promoted to NIH Distinguished Investigator, NIMH, NIH. Dr. Zarate is a fellow of the American College of Neuropsychopharmacology and member of the Society of Biological Psychiatry and the Society for Neuroscience. Dr. Zarate’s research focuses on the pathophysiology and development of novel therapeutics for treatment-resistant mood disorders as well as the study of biomarkers and neural correlates of treatment response.

Elisa Brietzke is a Psychiatrist and Professor at the Department of Psychiatry of Queen's University School of Medicine in Kingston, ON, Canada. She is attending psychiatrist at the Inpatient Unit from Kingston General Hospital and at Mood Disorders Research and Treatment Unit at Providence Care Hospital, both in Kingston, ON, Canada. Dr. Brietzke is also a member of the Centre for Neuroscience Studies (CNS) at Queen's University. She is a member of the Board of Councillors from the International Society of Bipolar Disorders (ISBD). The focus of her research is neurobiology and innovative interventions on mood disorders. She was awarded by a L'Oreal For Women in Science Award 2015 for her work on premature aging and inflammation in mood disorders.

Table of Contents

1. Ketamine, Clio, and the hippocratic triangled fragments of the history of ketamine
2. Ketamine’s potential mechanism of action for rapid antidepressive effects – a focus on neuroplasticity
3. Treatment resistant depression
4. Suicide in psychiatric disorders: rates, risk factors, and therapeutics
5. Overview of ketamine for major depression: efficacy and effectiveness
6. How to implement a ketamine clinic
7. Development of new rapid-action treatments in mood disorders
8. Closing remarks

What People are Saying About This

From the Publisher

Simple and evidence-based overview of the neurobiology and usage of ketamine as a therapeutic for treatment-refractory depression

Editorial Reviews

Reviewer: Aaron John Plattner, MD (Network180 )
Description: This book examines the growing use of ketamine for treatment-resistant depression.
Purpose: The authors note the use of ketamine for both FDA-approved and off-label uses and review the current available literature about how ketamine is being used and its potential future uses. These are worthy objectives given the widespread use of ketamine, and the authors meet them to the best of their ability given the limited data on this relatively new treatment option.
Audience: This book is intended primarily for those interested in potentially providing ketamine for their patients. However, anyone working with psychiatric patients would find it helpful because patients will be asking about ketamine and many are seeking treatment at ketamine clinics that continue to grow in number.
Features: The eight chapters discuss the basic understanding of what ketamine is and how it is proposed to be used to treat psychiatric disorders, review different treatment strategies for patients with treatment resistant depression or who are suicidal, provide practical instructions on implementing a ketamine clinic, and note other potential options that are "rapid acting treatments" for depression. Each chapter contains helpful illustrations and graphics and concludes with references.
Assessment: This is the first book that specifically focuses on ketamine for treatment-resistant depression. This topic has been covered in lectures, articles, and briefly in some textbooks, but this is the first book I have read that specifically covers it. Given the limited available data, the book succeeds in its stated goal to inform readers about what is currently known about ketamine. Updated editions will be needed to reflect the growing knowledge base and eventual treatment strategies using ketamine.

Doody's Review Service

"This is the first book that specifically focuses on ketamine for treatment-resistant depression. This topic has been covered in lectures, articles, and briefly in some textbooks, but this is the first book I have read that specifically covers it. Given the limited available data, the book succeeds in its stated goal to inform readers about what is currently known about ketamine. Updated editions will be needed to reflect the growing knowledge base and eventual treatment strategies using ketamine." —© Doody’s Review Service, 2020, Aaron Plattner, MD(Pine Rest Christian Mental Health Services), reviewer, expert opinion

From the Publisher